ESR1 and COVID-19: A recent publication revealed that raloxifene, which is a selective modulator of estrogen receptors and a potential antiviral medication in the treatment of coronavirus disease 2019 (COVID-19), enhanced the action of fluoxetine (14 mg/kg) in the MES test [14].